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Raf kinases mediate the phosphorylation of eukaryotic
translation elongation factor 1A and regulate its
stability in eukaryotic cells
C Sanges1,4,7, C Scheuermann2,4,7, RP Zahedi3, A Sickmann3, A Lamberti1, N Migliaccio1, A Baljuls2,4, M Marra5, S Zappavigna5,
U Rapp2,4, A Abbruzzese5,{, M Caraglia*,5 and P Arcari*,1,6
We identified eukaryotic translation elongation factor 1A (eEF1A) Raf-mediated phosphorylation sites and defined their role in
the regulation of eEF1A half-life and of apoptosis of human cancer cells. Mass spectrometry identified in vitro S21 and T88 as
phosphorylation sites mediated by B-Raf but not C-Raf on eEF1A1 whereas S21 was phosphorylated on eEF1A2 by both B- and
C-Raf. Interestingly, S21 belongs to the first eEF1A GTP/GDP-binding consensus sequence. Phosphorylation of S21 was
strongly enhanced when both eEF1A isoforms were preincubated prior the assay with C-Raf, suggesting that the eEF1A isoforms
can heterodimerize thus increasing the accessibility of S21 to the phosphate. Overexpression of eEF1A1 in COS 7 cells
confirmed the phosphorylation of T88 also in vivo. Compared with wt, in COS 7 cells overexpressed phosphodeficient (A) and
phospho-mimicking (D) mutants of eEF1A1 (S21A/D and T88A/D) and of eEF1A2 (S21A/D), resulted less stable and more rapidly
proteasome degraded. Transfection of S21 A/D eEF1A mutants in H1355 cells increased apoptosis in comparison with the wt
isoforms. It indicates that the blockage of S21 interferes with or even supports C-Raf induced apoptosis rather than cell survival.
Raf-mediated regulation of this site could be a crucial mechanism involved in the functional switching of eEF1A between its role
in protein biosynthesis and its participation in other cellular processes.
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Eukaryotic translation elongation factor 1A (eEF1A) is one of
the most abundant proteins in cells.1,2 In high vertebrates a
gene family encodes for two distinct isoforms, eEF1A1 and
eEF1A2.3 The coding region of the eEF1A gene is highly
conserved throughout eukaryotes. In humans, the almost
identical (92% sequence identity) amino-acid sequences of
the eEF1A isoforms differ in length only for one additional
C-terminal amino-acid residue present in the second isoform.
eEF1A belongs to the family of GTP-binding proteins and
promotes the GTP-dependent binding of aminoacyl-tRNA
to the A-site of the ribosome during the elongation cycle
in protein biosynthesis. Moreover, the GTPase activity of
eEF1A is also used to enhance the accuracy of codon
recognition.4,5 The functions of eEF1A in the elongation
cycle have been extensively investigated in eubacteria, for
example, Escherichia coli (EF-Tu) as well as in archaea,
for example, Sulfolobus sulfataricus6,7 and eukaryotes, for
example, Saccharomyces cerevisiae. These studies showed
the high conservation of the elongation factor between the
three kingdoms as well as among a wide range of different
species confirming its importance for life.
In higher vertebrates eEF1A1 is expressed during devel-
opment but is absent in the adult muscle and heart8,9 that, on
the other hand, express high levels of eEF1A2 as well as other
cell types including large motor neurons, islet cells in the
pancreas and neuroendocrine cells in the gut.10 Despite
sharing 92% sequence identity, paralogous human eEF1A1
and eEF1A2 have likely different functional profiles. eEF1A1
has been shown to be involved in additional non-canonical
functions, including actin-binding and bundling, apoptosis,
nuclear transport, proteasomal-mediated degradation of
damaged proteins, heat shock and transformation.11 It is not
yet clear how many of these non-canonical functions are
shared by the two isoforms but, in humans, eEF1A2 has been
shown to have oncogenic properties when overexpressed
inappropriately. It has been involved in the ovarian, breast,
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pancreatic, liver and lung cancer.12 Regarding this oncogenic
potential, the underlying cancerogenic mechanism needs to
be further investigated, including the identification of further
potential oncogenic mutations that have not been identified
yet.13
It is known that different signalling pathways, such as the
phosphatidylinositol 3-kinases/Protein Kinase B/mammalian
target of rapamycin and the Ras-mitogen-activated protein
kinase signalling cascades,14 are involved in the control of the
translation apparatus. Not much is clear about the direct
regulation of eEF1A even though several groups have been
studying phosphorylation and regulation of this elongation
factor.15 A summary of so far eEF1A-identified phosphoryla-
tion sites16–22 is reported in Table 1 of Supplementary
Information. Remarkably, eEF1A results to be a substrate
for phosphorylation by the classical protein kinase C (PKC)
isoforms in vitro. More precisely, PKC d phosphorylates
eEF1A at Threonine 431 (based on murine sequence)22 and
increases its activities in translation elongation whereas a
nuclear PKC isoform (PKCb1) could phosphorylate eEF1A2
on S53.21 Moreover, recent findings showed an in vivo
interaction between eEF1A andC-Raf kinase during a survival
response mediated by epidermal growth factor (EGF)-
dependent Ras/extracellular signal-regulated kinase (ERK)
pathway during the treatment of human lung cancer cells with
alpha interferon (IFNa).23,24 In detail, this interaction induced
eEF1A phosphorylation and increased its expression by
protecting the factor from proteasome-dependent degrada-
tion. In this study, we have defined the Raf kinase-mediated
phosphorylation sites in both eEF1A isoforms in vitro and their
possible involvement in the regulation of apoptosis in lung
cancer cells in vivo.
Results
Assays of Raf activity on eEF1A isoforms purified from
E. coli. On the basis of our previous results,23 we analyzed
the ability of Raf kinases to phosphorylate recombinant
eEF1A1-His and eEF1A2-His purified from E. coli in vitro
according to the procedures described in Supplementary
Information. The kinase assays were performed as reported
in Materials and Methods using recombinant B-Raf (wt B-Raf
or constitutively active mutant B-Raf V600E)25 as well as
C-Raf DD (constitutively active C-Raf DD)26 purified from
baculovirus-infected Sf9 cells as described previously.27
Inactive C-Raf K75D and B-Raf K75D were used as negative
controls. The results, reported in Figure 1, showed the
presence of a radioactive band with a size corresponding to
that of eEF1A1-His (50.5 kDa), thus indicating that wt B-Raf
and the constitutively active B-Raf V600E were able to
phosphorylate both eEF1A1-His and eEF1A2-His in vitro
(Figure 1a, lanes 1–4 and Figure 1d, lanes 1–2). To verify the
reproducibility of the results, the kinase assay was performed
using a different concentration of B-Raf obtaining similar
results (Figure 1g, lanes 1–2 and Figure 1k, lanes 1–2,
respectively). The correspondence of the 32P-signal with
eEF1A-His was confirmed by probing the membranes with
anti-eEF1A antibody (Figures 1b, e and h). In addition, the
radioactive band was also analyzed for trypsin digestion
B-Raf 95 kDa
eEF1A1-His
50.5 kDa
B-Raf 95 kDa
Mek 67 kDa Mek 67 kDa
Erk 41 kDa
Erk 41 kDa
eEF1A2-His
50.5 kDa
Erk 41 kDa
eEF1A Ab
eEF1A Ab
B-Raf Ab
B-Raf Ab
B-Raf 95 kDa
eEF1A1-His
50.5 kDa
Mek 67 kDa
Erk 41 kDa Mek 67 kDa
B-Raf 95 kDa
eEF1A Ab
B-Raf Ab eEF1A2-His 50.5 kDa
4321
4 5321
7654321
54321
Figure 1 B-Raf kinase assay of eEF1A1-His and eEF1A2-His. (a) Autoradiography of the assay on eEF1A1-His in the presence of B-Raf wt (10 ng/ml) and B-Raf V600E
(10 ng/ml), respectively. Lanes: 1, B-Raf wt (diluted 1 : 5) þ eEF1A1-His; 2, B-Raf wt þ eEF1A1-His; 3, B-Raf V600E (diluted 1 : 5) þ eEF1A1-His; 4, B-Raf V600E þ
eEF1A1-His; 5, B-Raf wt; 6, eEF1A1-His and 7, B-Raf wt þ Mek þ ERK. (b and c) Immunoblotting against antibody (Ab) anti-eEF1A and anti-B-Raf, respectively.
(d) Autoradiography of the assay on eEF1A2-His in the presence of B-Raf wt (10 ng/ml). Lanes: 1, B-Raf wt (diluted 1 : 5) þ eEF1A2-His; 2, B-Raf wt þ eEF1A2-His; 3, B-Raf
wt; 4 and B-Raf wt þ Mek þ ERK. (e and f) Immunoblotting against Ab anti-eEF1A and anti-B-Raf, respectively. (g) Autoradiography of the assay on eEF1A1-His in the
presence of B-Raf wt (20 ng/ml). Lanes: 1, B-Raf wt (diluted 1 : 5) þ eEF1A1-His; 2, B-Raf wt þ eEF1A1-His; 3, eEF1A1-His; 4, B-Raf wt and 5, B-Raf wt þ Mek þ ERK.
(h and i) Immunoblotting against Ab anti-eEF1A and anti-B-Raf, respectively. (k) Autoradiography of the assay on eEF1A2-His in the presence of B-Raf wt (20 ng/ml).
Lanes: 1, B-Raf wt (diluted 1 : 5) þ eEF1A2-His; 2, B-Raf wt þ eEF1A2-His; 3, B-Raf wt þ Mek þ ERK; 4, B-Raf wt and 5, eEF1A2-His
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(Supplementary Information). C-Raf DD instead did not
promote any phosphorylation on eEF1A1-His and eEF1A2-
His (Figure 2a, lanes 2 and 3, respectively). Therefore, based
on the hypothesis that the presence of both eEF1A isoforms
could enhance C-Raf activity in vitro, equal amounts of
eEF1A1-His and eEF1A2-His were mixed, preincubated at
37 1C in kinase buffer for 10min and then, in case of a C-Raf
DD-mediated phosphoryation, radioactively marked by 32P-
labelled ATP. A phosphorylation signal corresponding to the
size of eEF1A-His was observed in the sample containing
both proteins (Figure 2a, lane 4). This data could be
confirmed by the fact that the relative densitometric
evaluation of C-Raff DD autophosphorylation showed a
significant reduction in samples containing both isoforms
and in the control (Figure 2b, lanes 4 and 5). The
correspondence of the 32P-band and eEF1A-His was
confirmed by probing the same membrane with anti-eEF1A
antibody (Figure 2c).
Identification of phosphorylation sites on eEF1A1 and
eEF1A2 mediated by Raf kinases in vitro. To identify
the amino-acid residues of eEF1A1-His and eEF1A2-His
phosphorylated by Raf, recombinant eEF1A-His isoforms
expressed in E. coli were incubated with either B-Raf or
C-Raf DD in the presence of unlabelled ATP and analyzed
by mass spectrometry. As reported in Table 1, analysis of
the phosphopeptides showed that B-Raf phosphorylated
eEF1A1-His and eEF1A2-His, thus confirming the above
reported results of radioactive kinase assays. C-Raf DD did
not show any phosphorylation activity on eEF1A1-His, as
also observed for radioactive kinase assays whereas an
eEF1A2-His phosphopeptide containing phosphorylated S21
was detected. The latter result, apparently in contrast to the
radioactive kinase assays (Figure 2) can be explained by a
low C-Raf DD activity on eEF1A2-His that is not detectable
using conventional methods (e.g., in vitro kinase assay).
Thus, this finding is because of the specificity of mass
spectrometry. Table 1 and Supplementary Information report
the mass spectrometry identified phosphopeptides.
Identification of phosphorylation sites of eEF1A1
expressed in COS 7 cells. To assess if the identified
eEF1A phosphorylation sites were present in functional
and active proliferating cells, glutathione S-transferase
(GST)-eEF1A1 and eEF1A2-HIS were expressed in COS 7
cells and, 24 h after transfection, the recombinant proteins
were purified according to the procedure described in
Supplementary Information. Mass spectrometry analysis of
phosphopeptides obtained after tryptic digestion of the
proteins extracted from the SDS-PAGE, identified two
phosphorylation sites on GST-eEF1A1 (Table 2). One of
these sites (T88) was identical to that identified on
recombinant eEF1A1-His purified from E. Coli after in vitro
kinase assay in the presence of B-Raf (Table 1). No
phosphopeptides were instead identified on eEF1A2-HIS.
Expression and stability of eEF1A1 and eEF1A2 and
their mutants in COS 7. To study the relevance of eEF1A
phosphorylation sites found in vitro and in vivo, S21 and T88
on eEF1A1 and S21 on eEF1A2 were mutated using site-
directed mutagenesis and expressed in COS 7 cells. To
mimic the negative charge of the phosphate group, serine/
threonine was replaced with aspartic acid (S21D and T88D),
whereas the phosphorylation-deficient site was realized
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Figure 2 C-Raf DD kinase assay of eEF1A1-His and eEF1A2-His.
(a) Autoradiography. Lanes: 1, C-Raf DD; 2, C-Raf DD þ eEF1A1-His; 3, C-Raf
DD þ eEF1A2-His; 4, C-Raf DD þ eEF1A1-His þ eEF1A2-His and 5, positive
control C-Raf DD þ Mek þ ERK. (b) Relative densitometric evaluation of
C-Raf DD signal intensity. (c) Western blot with anti-eEF1A antibody. Each
measurement and western blot was carried out in triplicate. Error bars indicate
the maximum deviation from the mean value of two independent experiments
Table 2 Phosphorylation sites identified on eEF1A1 expressed in COS 7 cells
Substrates Phosphopeptide
sequence
Modified
amino-acid residue
GST-eEF1A1 K.YYVpTIIDAPGHRDFIK.N T88
GST-eEF1A1 K.p(YY)VTIIDAPGHR.D Y85 or Y86
Table 1 Phosphorylation sites identified on eEF1A1 and eEF1A2 expressed in Escherichia coli
Kinases Substrates Phosphopeptide sequence Modified amino-acid residue
B-Raf eEF1A1-His K.pSTTTGHLIYK.C S21
B-Raf eEF1A1-His K.YYVpTIIDAPGHRDFIK.N T88
B-Raf eEF1A2-His K.pSTTTGHLIYK.C S21
C-Raf DD eEF1A1-His – –
C-Raf DD eEF1A2-His K.pSTTTGHLIYK.C S21
C-Raf DD eEF1A1-His+eEF1A2-His K.pSTTTGHLIYK.Ca S21
aPhosphopeptide not ascribable specifically to any of two eEF1A isoforms
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by substituting serine/threonine with alanine (S21A and
T88A). To compare the expression levels of these proteins,
wt GST-eEF1A1, wt eEF1A1-HIS, wt eEF1A2-HIS and their
corresponding mutants were expressed for 48 h and
analyzed by immunoblotting. As reported in Figure 3,
western blot analysis with anti-His antibody or anti-GST
antibody of cell lysates showed that compared with wt, the
modified proteins were expressed at lower levels. In
particular, compared with wt eEF1A1-HIS, the densito-
metric evaluation of the band intensities from cell lysates
(Figure 3a) with respect to that of b-actin (Figure 3c) showed
that the expression level of S21A and S21D mutants was
lower than that of the T88A and T88D mutants (Figure 3b).
Similar results were also obtained by analyzing the
expression level of eEF1A1 and its mutant fused to GST.
In fact, western blots of the cell lysates (Figure 3d) with
anti-GST antibody confirmed the lower expression of the
GST-eEF1A1 mutants with respect to GST-eEF1A1 wt
(Figure 3e). Compared with wt eEF1A2-HIS, also the
expression of its corresponding S21 mutants with anti-His
antibody (Figure 3g) appeared to be reduced as shown by
the densitometric evaluation of the band intensity (Figure 3h)
from cell lysates with respect to that of b-actin (Figure 3i).
These findings suggested that compared with wt GST-
eEF1A1, eEF1A1-HIS and eEF1A2-HIS the respective
mutant proteins appeared less stable in vivo.
S21 has a crucial role in the ubiquitination status
and subsequent proteasomal degradation of eEF1A
isoforms in vivo. As reported above, mutation of RAF-
mediated phosphorylation sites on eEF1A interfere with
eEF1A protein expression levels. This indicates that Raf
might regulate the stability of both eEF1A isoforms in
an ubiquitin dependent and thus proteasome-dependent
manner. To investigate this possibility, COS 7 cells were
co-transfected transiently with eEF1A1-HIS or eEF1A2-HIS,
respectively, and HA-ubiquitin for 36 h. In the following 12 h,
cells were treated with the proteasomal inhibitor MG-132.
Overexpressed eEF1A-HIS isoforms were precipitated using
Ni-nitrilotriacetic acid (NTA) and immunoblotted against
HA-ubiquitin using an anti-HA antibody. As shown in
Figure 4 ubiquitination levels of both isolated phos-
phorylation resistant mutants of eEF1A-HIS (S21A and
T88A) were increased in comparison with the ubiquitina-
tion levels of isolated phosphorylation-mimicking mutants
(S21D and T88D) in MG132 non-treated cells (Figure 4a).
Remarkably, in MG132-treated cells ubiquitination levels of
isolated eEF1A1-HIS wild-type and corresponding mutants
were comparable (Figure 4b). Similar results were obtained
when eEF1A2-HIS wt and corresponding mutants (S21A and
S21D) were co-expressed together with HA-ubiquitin in COS
7 cells (Figure 4e). In detail, the ubiquitination level of
eEF1A2-HIS S21A was increased in comparison with the
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Figure 3 Expression levels of GST-eEF1A1, eEF1A1-HIS and eEF1A2-HIS and corresponding mutants in COS 7 cells. (a, g and d) Western blots of cell lysates
with antibody anti-His and anti-GST, respectively. (a) Lanes: 1, eEF1A1-HIS wt; 2, eEF1A1-HIS S21A; 3, eEF1A1-HIS S21D; 4, eEF1A1-HIS T88A; 5, eEF1A1-HIS T88D.
(d) Lanes: 1, GST-eEF1A1 wt; 2, GST-eEF1A1 S21A; 3, GST-eEF1A1 S21D; 4, GST-eEF1A1 T88A; 5, GST-eEF1A1 T88D. (g) Lanes: 1. eEF1A2-HIS wt; 2, eEF1A2-HIS
S21A and 3, eEF1A2-HIS S21D. (b, e and h) Relative band intensity evaluation. (c, i and f) Western blots of cell lysates with antibody anti-b-actin and anti-GAPDH,
respectively. Each measurement and western blot was carried out in triplicate. Error bars indicate the maximum deviation from the mean value of two independent experiments
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ubiquitination level of eEF1A2-HIS S21D in the absence of
MG132, whereas in the presence of MG132 ubiquitina-
tion levels of eEF1A2-HIS wt, eEF1A2-HIS S21A and
eEF1A2-HIS S21D were quite similar (Figure 4f). Similar
results were also obtained when in a similar independent
experiment. Immunoblotting analysis with anti-His antibody
of the cell extracts after His-pull-down showed that compared
with intact eEF1A1 and eEF1A2, the polyubiquitination level
was slightly higher for the mutants (Figures 4i and k,
respectively).
S21 positively regulates apoptosis in H1355 cells. In
order to assay the biological effects of the eEF1A isoforms
and their mutants, H1355 cells were transfected with wt
eEF1A-HIS and the corresponding S21A and S21D
constructs. As reported in Figure 5, compared with wt,
transfections of H1355 cells with eEF1A-HIS mutants
showed in general an increase in the apoptosis evaluated
after 72 h by FACS analysis following double labelling of the
cells with annexin V and propidium iodide. In particular,
eEF1A1-HIS S21A and S21D mutants induced mainly an
increase of early apoptosis whereas eEF1A2-HIS S21A
and S21D mutants induced an increase of late apoptosis.
Details regarding the FACS analysis of the samples are
reported in Supplementary Information.
Discussion
In this work, the role of eEF1A post-translational modifications
induced by its interaction with Raf kinases has been
examined. The work was based on our previous finding that
following treatment of a human epidermoid cancer cell line
(H1355) with INFa, revealed a phosphorylation of eEF1A
mediated by C-Raf kinase, following activation of a survival
pathway induced by the EGF receptor.23 Therefore, the aim
was the identification of the specific amino-acid residues of
eEF1A isoforms phosphorylated by Raf using a proteomic
approach. Here, we describe for the first time that both
eEF1A1 and eEF1A2 were phosphorylated in vitro by B-Raf
and C-Raf on S21. This residue belongs to the first consensus
sequence (G,A)XXXXGK(T,S) of the GTP/GDP-binding site
of GTP-binding proteins28 that are highly conserved in both
human variants (G14HVDSGKST in both eEF1A1 and
eEF1A2).
According to the 3D model of EF1AGDPEF1B from
yeast, the S21 (S21 in human eEF1A1 and eEF1A2) side
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Figure 4 Ubiquitination assay of eEF1A1-HIS and eEF1A2-HIS and their mutants. After cotransfection of COS 7 cells with wt eEF1A-HISs and corresponding mutants
with HA-ubiquitin wt and treatment of cells in the absence () or in presence (þ ) of MG132, cell extracts were analyzed after pull-down for eEF1A1-HIS (a, b, i) and eEF1A2-
HIS (e, f, k), respectively, by immunoblotting with anti-HA (a, b, e, f) and anti-His (i, k) antibodies. (a, b, i) Lanes: 1, eEF1A1-HIS wt; 2, eEF1A1-HIS S21A; 3, eEF1A1-HIS
S21D; 4, eEF1A1-HIS T88A and 5, eEF1A1-HIS T88D. (e, f, k) Lanes: 1, eEF1A2-HIS wt; 2, eEF1A2-HIS S21A and 3, eEF1A2-HIS S21D. Band intensities were analyzed
using Image J software (National Institutes of Health, Bethesda, MD, USA) (c, d, g, h, j and l)
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chain is linked directly to the oxygen of both phosphates of the
GDP nucleotide.29 In addition, also T22, D156, S192, G193
and W194 (all in domain I) are important for the binding of
GTP/GDP ligands.30 In fact, mutations of the amino-acid
residues involved in the binding of guanine nucleotide such as
D156N of yeast EF1A resulted in a marked reduction in
translational fidelity.31 Therefore, the binding of the guanine
nucleotides on eEF1A could be potentially prevented by
phosphorylation of the S21 residue. This phosphorylation
could cause a conformational change that directs eEF1A to
interact with other partners leading to different functions far
from protein biosynthesis, such as actin bundling, essential for
regulation of actin cytoskeleton and cell morphology during
several cellular processes.32 These observations are indir-
ectly confirmed by the finding that GST-eEF1A1 expressed in
normal proliferating cells (COS 7), did not show any modi-
fications of S21. In fact, in a contest of normal cell growth,
most of eEF1A molecules present in the cells are involved in
its canonical function during protein biosynthesis.33
We also found that eEF1A1 is specifically phosphorylated
on T88 by B-Raf in vitro. This phosphorylation on T88was also
identified using mass spectrometry on eEF1A1 expressed in
proliferating COS 7 cells. However, we cannot affirm that T88
in vivo phosphorylation is due to a specific B-Raf activity on
eEF1A1. The fact that phosphorylated T88 was found only on
eEF1A1 suggests that this post-translational modification is
due to structural differences between eEF1A1 and eEF1A2.
Thus, a participation of phosphoT88 in that residue corre-
sponding specific cellular events with respect to those
involving the phosphorylation of S21 is conceivable.
We also identified in proliferating COS 7 cells a peptide
containing not clearly defined phosphorylation at the level of
Y85 or Y86. Large-scale proteomics studies20 already
revealed that, besides Y86, other tyrosine residues present
in both human eEF1A variants are phosphorylated. Albeit
both isoforms share a sequence homology of 98%, only
eEF1A1, as we also confirmed by our results, is phosphory-
lated on Y86. Moreover, it has been recently reported that
eEF1A1 and eEF1A2 interact with SH2 and SH3 domains of
different signalling molecules and the binding interaction sites
have been localized at the level of tyrosine residues (Y86 and
Y167) of the G-domain of eEF1A.34
To study the relevance of these identified phosphorylated
residues, namely S21 and T88, we analyzed the biochemical
function of mutated eEF1As by transient expression in COS 7
cells, even though no phosphorylation for S21 was observed
in vivo. One possible explanation for the lack of S21
phosphorylation in COS 7 cells might be ascribed to the fact
that this post-translational modification could impair the
involvement of eEF1A in protein synthesis (a fundamental
process in active proliferating cells). Instead, this modification
might occur in tumor cells following the activation of a signal
transduction pathway inducing tumorigenesis. Considering
the fact that Raf kinases have an important role in tumorigen-
esis and inter alia cellular proliferation, a Raf-mediated
phosphorylation of eEF1A isoforms in vivo is expectable and
further confirmed by the in vitro data. Furthermore, S21 is part
of the GDP/GTP-binding pocket and thus has an important
structural role for the function of eEF1A. At the same time it is
also a possible phosphorylation residue (as evidenced by the
in vitro data shown here) affecting the eEF1A expression
levels in COS 7 cells. Compared with the corresponding wt
eEF1A, overexpression of eEF1A1 and eEF1A2 S21A/D
mutants in COS 7 cells showed a marked reduction of protein
levels as determined by western blot of cell lysates. This
reduction was most likely due to an increase of their
proteasomal degradation as indicated by western blot
analysis of pull-down samples from cells co-transfected with
eEF1A constructs and HA-ubiquitin in the absence or
presence of the proteasomal inhibitor MG132. Protein levels
of the ubiquitinated phospho-deficient mutant (S21A) were
higher in comparison with protein levels of the ubiquitinated
phospho-mimicking mutant S21D (Figure 4). Consequently,
we assume that S21 is a crucial site for the half-life of eEF1A
and its phosphorylation could be a regulatory switch for other
functional roles of eEF1A. Moreover, the finding that C-Raf
required the presence of both eEF1A isoforms for its
phosphorylation activity in vivo, suggested the formation of a
potential eEF1A heterodimer. Remarkably, EF1A dimeriza-
tion has been already described for Tetrahymena EF1A. In
that case, EF1A, that is also an activator of a PI 4-kinase,
bound actin and increased actin bundling.35 EF1A bundles
filamentous actin through dimer formation whereas EF1A
monomers do not.36
In order to support the potential interaction between eEF1A
isoforms in vivo, recombinant GST-eEF1A1 wt and mutants
were cotransfected with eEF1A2-HIS wt in COS 7 cells and
then analyzed by western blot after GST pull-down. As shown
in Figure 6, the expressed proteins were detected with both
anti-GST and anti-His antibodies. In particular, the expression
level of GST-eEF1A1 and S21D and T88D mutant was quite
similar to that observed in the experiment reported in Figure 3.
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Figure 5 Effects of transfection with eEF1A-HIS isoforms and their S21 mutants
on apoptosis in H1355 cells. FACS analysis after double labelling with annexin V
and propidium iodide of H1355 cells transfected with eEF1A-HIS constructs for 72 h
as described in Materials and Methods and Supplementary Information. White bars:
percentage of annexin V-FITC and PI positive (late apoptosis). Black bars:
percentage of annexin V-FITC positive (early apoptosis). Samples: 1, control cells;
2, cells treated with lipophectamine; 3, cells transfected with void vector; 4, eEF1A1-
HIS wt, 5, eEF1A1-HIS S21A; 6, eEF1A1-HIS S21D; 7, eEF1A2-HIS wt, 8, eEF1A2-
HIS S21A and 9, eEF1A2-HIS S21D. Error bars indicate the maximum deviation
from the mean value of two independent experiments
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Also similar was the level of the signal as detected with
anti-His antibody. These results confirmed in vivo the
eEF1A1eEF1A2 interaction observed in vitro. The hetero-
dimerization hypothesis was also investigated generating a
docking model of the two isoforms interaction (r-1.pdb) at
GRAMM-X Protein–Protein Docking Web Server v.1.2.037,38
using 3D models of eEF1A1 (eEF1A1.pdb) and eEF1A2.
(eEF1A2.pdb). The pdb files for human eEF1A1 and eEF1A2
were generated at Swiss-Model Server39 using as template
the structure of yeast eEF1A (PDB ID: 1F60, chain A).29
As illustrated in Figure 7, the docking model obtained
supports the formation of a possible heterodimer between
eEF1A1 and eEF1A2. In particular, this model shows that
the M-domain of one isoform is in contact to the G-domain
of the other and vice versa. The heterodimer formation
somehow could induce a conformational change in one or in
both eEF1A isoforms that allows the phosphorylation of S21.
However, because of the high sequence similarity between
eEF1A isoforms, the formation of eEF1A1 or eEF1A2
homodimer cannot be excluded.
The effects of the eEF1A isoforms in mediating cell
proliferation or apoptosis might depend on their respective
intracellular abundance.40 Therefore, we analyzed the biolo-
gical effects of eEF1A wt and mutants during their transient
overexpression in H1355 cells. The data obtained showed
that eEF1A-mutated recombinant proteins, lacking the amino-
acid residues important for the phosphorylation (T/S ex-
changed against A/D by site-directed mutagenesis) and thus
unable to be regulated by C-Raf, induced apoptosis rather
than cell survival. This result is in agreement with our previous
work showing that the upregulation of the intracellular content
of eEF1A is associated to an increase in the phosphorylation
of serine and threonine residues of the protein mediated by
C-Raf and that this effect appeared to have a pro-survival
function.23 Interestingly, eEF1A1 S21 mutants induced an
increase of early apoptosis whereas eEF1A2 S21 mutants
induced an increase of late apoptosis. The latter aspect may
be also in agreement with the antiapoptotic role proposed for
eEF1A241 as the lower stability of the eEF1A2 mutants
probably abolishes its protective function and causes apopto-
tic events.
Conclusions
In conclusion, we have identified eEF1A amino-acid residues
(S21 and T88) that are phosphorylated by Raf kinase in vitro
and eEF1A amino-acid residues (T88 and Y85/86) that are
phosphorylated by a not identified kinase in vivo.Mutations of
S21 and T88 affect the stability of the elongation factor in vivo.
These residues havemost likely an important functional role in
the control of cellular process, such as cell proliferation and
apoptosis.
Materials and Methods
Expression and purification of recombinant eEF1A1-His and
eEF1A2-His from E. coli. eEF1A1 and eEF1A2 cDNAs were cloned in
pET22b(þ ) expression vectors (Novagen, Darmstadt, Germany) in frame to the
His-Tag sequence and overexpressed in E. coli strains (Rosetta, BL21C43)
according to the procedure reported in Supplementary Information. Activity of the
purified proteins was tested in vitro according to the procedure already described42
and summarized in Supplementary Information.
Expression and purification of recombinant eEF1A1 and eEF1A2
from COS 7 cells. eEF1A1 and eEF1A2 cDNAs were cloned in mammalian
expression vectors (pEBG and pCDNA 3.1, respectively) and expressed in COS 7
cells. Because of the lack of an isoform-specific antibody raised against the two
isoforms, eEF1A1 was fused to GST (GST–eEF1A1) whereas eEF1A2 was
provided with a His-Tag (eEF1A2-HIS). Vectors were transfected with jet
polyethylenimine solution (Polyplus tranfection) according to the manufacturer’s
protocol. The procedure for the purification of both proteins is reported in
Supplementary Information.
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Figure 7 Imitation of a 3D model of an eEF1A1eEF1A2 heterodimer.
The heterodimer representation was obtained from the molecular docking pdb
file (r-1.pdb) using PyMol software (DeLano Scientific LLC, San Carlos, CA, USA).
In both eEF1A isoforms, the position of S21 is highlighted
1
GST-eEF1A1
GST Ab
76.5 kDa
eEF1A2-HIS
His Ab
50.5 kDa
160
140
120
100G
ra
y 
Va
lu
e
80
0 200 400 600 800
Distance (pixels)
1000 1200
G
ra
y 
Va
lu
e
0
100
150
200 400 600 800
Distance (pixels)
1000 1200
32
Figure 6 Cotransfection of GST-eEF1A1 and eEF1A2-HIS in Cos 7 cells. GST-
eEF1A1 wt and mutants were cotransfected with eEF1A2-HIS wt in COS 7 cells.
After 24 h, the cells were harvested, lysed and analyzed after GST pull-down with
antibody anti-GST (GST Ab, a) and anti-His (His Ab, c). Lanes: 1, cells transfected
with GST-eEF1A1 wt and eEF1A2-HIS wt; 2, cells transfected with GST-eEF1A1
S21D and eEF1A2-HIS wt; 3. Cells transfected with GST-eEF1A1 T88D and
eEF1A2-HIS wt. Band intensities were evaluated with Image J software (b and d)
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In vitro kinase assay. The Raf kinase assay was performed in vitro on recombinant
eEF1A-His purified from E. coli. Depending on the kinase and the substrate, recombinant
proteins were mixed in a 1 : 3/1 : 5 or 2 : 3/2 : 5 ratio ensuring substrate excess. The reac-
tion mixture contained 300 or 600 ng of purified kinase, purified substrate 600–1000 ng,
1 kinase buffer (10 kinase buffer: 25 mM glycerol-phosphate, 50 mM TrisHCl,
pH 7.5, 2 mM DTT, 10 mM MgCl2 and 25 mM ATP) to a final volume of 30ml. For the
radioactive labelling assay 5–10mCi [g-32P]ATP (Hartmann Analytics, Braunschweig,
Germany), corresponding to 0.5–1.0ml, were added. The mixture was incubated at 37 1C
for 1 h on a thermomixer at 600 r.p.m. The reaction was stopped by addition of 4
Laemmli loading buffer (2.4 ml 1 M Tris pH 6.8, 0.8 g SDS, 4 ml 100% glycerol, 0.01%
bromophenol blue, 1 ml b-mercaptoethanol and 2.8 ml water),43 and analyzed by immuno-
blotting with phosphospecific antibodies or, in case of radioactive labelling, the nitrocellulose
membrane was exposed to an X-ray film at80 1C overnight (ON). The protein concentra-
tion was determined according to Lowry.44 Analysis of trypsin digestion of the radio-labelled
band extracted from gels was performed according to van der Geer and Hunter.45
Vector construction. Full-length eEF1A1 and eEF1A2 cDNAs were cloned in
PET-22b(þ ) using pAN746 and eEF1A2 pcDNA 3.1. (gift of Charlotte R Knudsen,
Aarhus)47 vectors as templates. The following primers were used: EF1 (forward)
50-CCCTAAAAGCCCATATGGGAAAGG-30 and EF2 (reverse) 50-CTTCCACCAC
GGATCCAGAGTGGG-30. A2 (forward) 50-TGGAATTCACTCATATGGGCAAG-30;
A2 (reverse) 50-CTCGAGTCAGTGATGGTGATG-30.
Full-length eEF1A1 cDNA was cloned in pcDNA 3.1 using the pAN7 vector as a
template. The following primers were used: EFB (forward) 50-GCCAAAATGGG
ATCCGAAAAGACT-30 corresponding to the region containing M1GKEKT and
EFA (reverse) 30-ATTCATTTACCGGTCTGAGCTTTCTG-50 overlapping with the
Q456KAQKAK (stop codon) region of eEF1A.
For the pEBG vector containing full-lenght EF1A1 fused to GST the following
primers were used: Pebg (forward) 50 AAAAAAGGATCCATGGGAAAGGAAAAG
ACTCATATCAACATTGTC-30 and PEBG (reverse) 50-AAAAAATCTAGATCATTTA
GCCTTCTGAGCTTTCTGGGCAGACTT-30.
The eEF1A mutants were generated by site-direct mutagenesis using the
corresponding vectors as templates. The following self-complementary oligonucleo-
tides were used: eEF1A1 S21A (forward): 50-GTA GAT TCG GGC AAG GCG ACC ACT
ACT GGC CAT-30, eEF1A1 S21A (reverse): 50-ATG GCC AGT AGT GGT CGC CTT
GCC CGA ATC TAC-30, eEF1A1 S21D (forward): 50-GTA GAT TCG GGC AAG GAT
ACC ACT ACT GGC CAT-30, eEF1A1 S21D (reverse): 50-ATG GCC AGT AGT GGT
ATC CTT GCC CGA ATC TAC-30, eEF1A1 T88A (forward): 50-AGC AAG TAC TAT GTG
GCG ATC ATT GAT GCC CCA-30, eEF1A1 T88A (reverse): 50-TGG GGC ATC AAT
GAT CGC CAC ATA GTA CTT GCT-30, eEF1A1 T88D (forward): 50-AGC AAG TAC TAT
GTG GAT ATC ATT GAT GCC CCA-30, eEF1A1 T88D (reverse): 50-TGG GGC ATC
AAT GAT ATC CAC ATA GTA CTT GCT-30, eEF1A2 S21A (forward): 50-GTG GAC TCC
GGA AAG GCG ACC ACC ACG GGC CAC-30, eEF1A2 S21A (reverse): 50-GTG GCC
CGT GGT GGT CGC CTT TCC GGA GTC CAC-30, eEF1A2 S21D (forward): 50-GTG
GAC TCC GGA AAG GAT ACC ACC ACG GGC CAC-30, eEF1A2 S21D (reverse):
50-GTG GCC CGT GGT GGT ATC CTT TCC GGA GTC CAC-30.
Following amplification, performed with Pfu polymerase (Stratagene, Santa Clara,
CA, USA), the PCR products were treated with Dpn I endonuclease (Fermentas,
Milan, Italy, 1 h at 37 1C plus inactivation for 30 min at 80 1C) specifically digesting
the methylated parental DNA strand. The duration of the elongation cycle was
calculated based on the activity of the Pfu polymerase (2 min/1000 bp).
Pull-down and western blot analysis. Pull-down of GST-eEF1A1 or
eEF1A2-HIS was performed using GST-sepharose (Amersham, Milan, Italy) or Ni-NTA
agarose (Qiagen, Milan, Italy), respectively. Cell extracts (500mg) were incubated with
equal amounts of pre-equilibrated resin (150ml slurry/1 mg protein extract) for 2 h at room
temperature (RT) or ON at 4 1C, respectively. After the incubation, the resin was washed
two times (centrifugation for 2 min at 2000 r.p.m. and 4 1C) in 1 ml of 1 phosphate
buffered saline (PBS), in the case of GST-sepharose, or in 50 mM NaH2PO4, 300 mM
NaCl, 20 mM imidazole, in the case of Ni-NTA to reduce nonspecific bound proteins,
0.05% Tween 20, pH 8.0, resuspended in 30ml of 4 Laemmli loading buffer, heated to
95 1C for15 min and subjected to western blot analysis. Blots were developed using
enhanced chemiluminescence detection (SuperSignal West Pico, Pierce, Milan, Italy).
All films were scanned using Adobe photoshop software (San Jose, CA, USA).
Antibodies used were as follows: mouse monoclonal antibody anti-EF1A
(Upstate, Billerica, MA, USA), rabbit polyclonal antibody anti-GST (Santa Cruz,
Santa Cruz, CA, USA), mouse monoclonal antibody anti-actin (Santa Cruz), mouse
monoclonal antibody anti-His (Qiagen) and rabbit polyclonal anti-HA antibody
(Abcam, Cambridge, MA, USA).
Mass spectrometry measurements. Mass spectrometry analysis of
eEF1A-His samples overexpressed in E. coli was performed after separation of the
recombinant proteins by SDS-PAGE (NuPAGE (Darmstadt, Germany) Novex 4–12%
Bis-Tris gels; MOPS buffer system). Gels were subjected to silver staining, and the
respective bands were excised and washed according to Shevchenko et al.48
Mass spectrometry analysis of GST-eEF1A and eEF1A2-HIS overexpressed in
COS 7 cells was performed after separation of the proteins on 4–12% BisTris SDS
Gels (Invitrogen, Karlsruhe, Germany). Afterwards protein band was visualized
according to Blum et al.49 with slight modifications, excised, washed and in-gel
digested as described previously.50,51
Detailed procedures for mass spectrometry measurements are reported in
Supplementary Information.
Cell culture and transfection. COS 7 cells (African green monkey kidney)
were grown in Dulbecco’s modified Eagle medium (Gibco, Monza, Italy) with 10%
fetal bovine serum (FBS), 2 mM L-glutamine (Gibco) and antibiotics (penicillin–
streptomycin, Gibco). The human lung epidermoid carcinoma cell line (H1355),
obtained from American Type Tissue Collection (Rockville, MD, USA), was grown
in an RPMI 1640 medium supplemented with heat-inactivated FBS, 100 U/ml
penicillin, 100m/ml streptomycin and 1% L-glutamine at 37 1C. The cells were
grown in a humidified atmosphere of 95% air, 5% CO2 at 37 1C.
Cells were detached from confluent 100-mm dishes. About 2 105 cells were
incubated in electroporation buffer (20 mM 4-(2-hydroxyethyl)-1-piperazineethane-
sulfonic acid (HEPES), 137 mM NaCl, 5 mM KCl, 0.7 mM Na2HPO4 and 6 mM
glucose) and 15mg/ml of DNA construct in 20 mM HEPES. Cells were
electroporated at 250 V and at 975 mF for 6 s and incubated at 37 1C for 24 h.
Following incubation the cells were processed for western blotting analysis and
apoptosis detection as described below.
Immunoprecipitation. H1355 cells were scraped, washed twice in cold PBS
and resuspended in 20–40ml of lysis buffer (50 mM Tris-HCl pH 7.4, 1% NP40,
0,25% sodium deoxycholate, 150 mM NaCl, 1mg/ml aprotinin, leupeptin, pepstatin,
1 mM Na3VO4 and 1 mM NaF) for 30 min on ice and centrifuged at 14 000 g
for 20 min at 4 1C. Total protein extracts (500mg) were subjected to immuno-
precipitation with 2 mg of anti-eEF-1A for 16 h at 4 1C. Immune complexes were
bound to 20ml of protein A-agarose for 2 h at 4 1C. The protein A-agarose/immune
complex was washed four times with cold PBS and resuspended in 20 ml of SDS
loading buffer, heated for 5 min at 95 1C and subjected to western blotting analysis.
Cytosolic proteins (2 mg) were separated by SDS-PAGE, electrotransferred to
nitrocellulose and probed with anti-eEF-1A and anti-His antibodies. Blots were
developed using enhanced chemiluminescence detection reagents (SuperSignal
West Pico, Pierce) and exposed to X-ray films. Bands were quantified by using
Adobe photoshop software.
Ubiqutination assay. COS 7 cells were grown and co-transfected, as above
mentioned, either with eEF1A1-HIS or with eEF1A2-HIS constructs and HA-ubiquitin for
36 h and subsequently incubated in the presence or absence of MG132 (Calbiochem,
Milan, Italy) for 12 h. Immunoblotting analysis of Ni-NTA isolated proteins has been
performed as above reported, probing the corresponding membrane with anti-HA
antibody.
Flow cytometric analysis of apoptosis. Apoptotic cell death was
analysed by Annexin-V–fluorescein isothiocyanate (FITC) staining. Annexin-V–
FITC binds to phosphatidylserine residues, which are translocated from the inner to
the outer leaflet of the plasma membrane during the early stages of apoptosis.
Labelling of apoptotic cells was performed using an Annexin-V kit (MedSystems
Diagnostics, Vienna, Austria). Briefly, after transfection, H1355 cells were incubated
in complete RPMI 1640 for 72 h. Subsequently, all cells (flowing and attached)
were incubated with Annexin-V–FITC in a binding buffer (provided by the
manufacturer) for 10 min at RT, washed and resuspended in the same buffer
as described by the manufacturer. Apoptosis was evaluated measuring the % of
mean fluorescence intensity (% MFI) using FL1-H (Log scale) by the FACSCalibur
software (Applied Biosystems, Monza, Italy). For each sample, 20 000 events were
acquired. Analysis was carried out by triplicate determination on at least three
separate experiments.
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